Logo - springer
Slogan - springer

New & Forthcoming Titles | Progress in Inflammation Research ( Miscellaneous)

Progress in Inflammation Research

Progress in Inflammation Research

Series Editors: Parnham, M.J., Schmidtko, A., Maier, T.J., Ricciotti, E.

Continuation of the series "Agents and Actions Supplements", discontinued on 04-Dec-2001

ISSN: 0379-0363

EDITORS

Series Editors

Prof. Michael J. Parnham, PhD, C.Biol.MRSB, FBPhS studied Pharmacology at Chelsea (now King's) College London, including a year in the department of subsequent Nobel Prize winner, John R. Vane, at the Royal College of Surgeons. He received his PhD from Bristol University in 1976) and carried out postdoctoral research on prostaglandins and chronic inflammation with Ivan Bonta at Erasmus University Rotterdam, The Netherlands for which he was awarded the Goslings Prize of the Netherlands Society for Antirheumatic Therapy. From 1980, he spent a decade in anti-inflammatory drug research with A. Nattermann and subsequently, Rhone-Poulenc in Cologne, Germany. He and his colleagues received in 1990 the Prix Galien Germany for development of a novel organoselenium approach to anti-inflammatory therapy. In the same year, Dr. Parnham established a consultancy in Bonn and gained his habilitation at Goethe University Frankfurt where he taught immunopharmacology to pharmacists. Appointed Professor in Frankfurt in 1998, Dr. Parnham established laboratories in pharmacology and toxicology at PLIVA Pharmaceuticals, developing biosimilar agents and working on novel anti-inflammatory macrolides. Following acquisition by GSK in 2006, he was Director of Preclinical Discovery. From 2012 to 2019, Prof. Parnham built up preclinical research in the Fraunhofer Institute of Molecular Biology & Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP, in Frankfurt am Main. Currently, he is Chief Scientific Officer at EpiEndo Pharmaceuticals, Rejkjavik, continuing to work on macrolides and respiratory inflammation.
Prof. Parnham was co-founder in 1983 of the European Workshop on Inflammation, and its secretary until 1999. During this time he was Co-Editor of the peer-reviewed journal Agents and Actions, presiding as Managing Editor (1992-2013) over its transformation to Inflammation Research. He is co-editor of the monograph series Progress in Inflammation Research (PIR) and of Milestones in Drug Therapy (MDT) as well as of the textbook, Principles of Immunopharmacology, now in its 4th edition. He is also Editor-in-Chief of the Springer Reference Compendium of Inflammatory Diseases. Prof. Parnham has lectured extensively and organised symposia on various aspects of immunopharmacology and anti-inflammatory therapy and has published more than 185 peer-reviewed articless. In 2015, he received a Lifetime Achievement Award from the International Association of Inflammatory Societies (IAIS).
Prof. Achim Schmidtko, PhD, MD (born 1972) studied pharmacy and medicine at the Goethe University Frankfurt, Germany, and received the license to practice pharmacy and medicine in 1998 and 2004, respectively. He earned his PhD and MD degree at the Goethe University Frankfurt and is a medical specialist in Pharmacology and Toxicology and in Clinical Pharmacology. From 2012 to 2015 he was Professor of Pharmacology and Toxicology at the Witten/Herdecke University, Germany. Since 2016 he is Professor of Pharmacology and Director of the Institute of Pharmacology and Clinical Pharmacy at the Goethe University Frankfurt. His key research focus is on the characterization of cellular and molecular mechanisms of pain processing. His research group uses a variety of methods from classical pharmacology, in vivo experimental models, microscopic imaging, and molecular biology.
Prof. Thorsten J├╝rgen Maier PhD, MD studied biochemistry and medicine at the Goethe University Frankfurt a.M., Germany. He earned his PhD in pharmacy and MD degree at the Goethe University Frankfurt am Main/Germany. In 2014 he accepted an offer as Professor of Pharmacology at the Aarhus University Denmark. Since 2019 he is appointed Professor and research group leader in the field of pharmacy and pharmacology at the Paul-Ehrlich Institute in Langen/Germany. For his research he received a number of grants and awards including a Heisenberg stipend of the Deutsche Forschungsgemeinschaft (DFG). His research group is interested in endogenous anti-inflammatory mediators and a possible use of derivatives of these mediators as drug candidates. For his research he uses a broad spectrum of methods covering molecular biology, cell culture assays up to animal models of disease.

Alerts for this Series

Get the table of contents of every new volume published in Progress in Inflammation Research.

Additional information